Literature DB >> 31576303

Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?

Matthew Zibelman1, Elizabeth R Plimack1.   

Abstract

Entities:  

Year:  2019        PMID： 31576303      PMCID： PMC6685891          DOI： 10.21037/atm.2019.04.57

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  18 in total

1.  Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.

Authors:  R I Fisher; S A Rosenberg; G Fyfe
Journal:  Cancer J Sci Am       Date:  2000-02

Review 2.  Cytokine Therapy.

Authors:  Ann W Silk; Kim Margolin
Journal:  Hematol Oncol Clin North Am       Date:  2019-01-28       Impact factor: 3.722

3.  Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

Authors:  Jacob Schachter; Antoni Ribas; Georgina V Long; Ana Arance; Jean-Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian Blank; Teresa M Petrella; Omid Hamid; Honghong Zhou; Scot Ebbinghaus; Nageatte Ibrahim; Caroline Robert
Journal:  Lancet       Date:  2017-08-16       Impact factor: 79.321

4.  Spontaneous remission of renal cell carcinoma: a case report and immunological correlates.

Authors:  Y A Abubakr; T H Chou; B G Redman
Journal:  J Urol       Date:  1994-07       Impact factor: 7.450

5.  Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

Authors:  Diwakar Davar; Hong Wang; Joe-Marc Chauvin; Ornella Pagliano; Julien J Fourcade; Mignane Ka; Carmine Menna; Amy Rose; Cindy Sander; Amir A Borhani; Arivarasan Karunamurthy; Ahmad A Tarhini; Hussein A Tawbi; Qing Zhao; Blanca H Moreno; Scott Ebbinghaus; Nageatte Ibrahim; John M Kirkwood; Hassane M Zarour
Journal:  J Clin Oncol       Date:  2018-10-25       Impact factor: 44.544

6.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Authors:  Bernard Escudier; Anna Pluzanska; Piotr Koralewski; Alain Ravaud; Sergio Bracarda; Cezary Szczylik; Christine Chevreau; Marek Filipek; Bohuslav Melichar; Emilio Bajetta; Vera Gorbunova; Jacques-Olivier Bay; Istvan Bodrogi; Agnieszka Jagiello-Gruszfeld; Nicola Moore
Journal:  Lancet       Date:  2007-12-22       Impact factor: 79.321

7.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Authors:  Alexander M M Eggermont; Stefan Suciu; Mario Santinami; Alessandro Testori; Wim H J Kruit; Jeremy Marsden; Cornelis J A Punt; François Salès; Martin Gore; Rona Mackie; Zvonko Kusic; Reinhard Dummer; Axel Hauschild; Elena Musat; Alain Spatz; Ulrich Keilholz
Journal:  Lancet       Date:  2008-07-12       Impact factor: 79.321

8.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

Authors:  J M Kirkwood; M H Strawderman; M S Ernstoff; T J Smith; E C Borden; R H Blum
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

9.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Authors:  Suzanne L Topalian; Mario Sznol; David F McDermott; Harriet M Kluger; Richard D Carvajal; William H Sharfman; Julie R Brahmer; Donald P Lawrence; Michael B Atkins; John D Powderly; Philip D Leming; Evan J Lipson; Igor Puzanov; David C Smith; Janis M Taube; Jon M Wigginton; Georgia D Kollia; Ashok Gupta; Drew M Pardoll; Jeffrey A Sosman; F Stephen Hodi
Journal:  J Clin Oncol       Date:  2014-03-03       Impact factor: 44.544

10.  NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.

Authors:  Deborah H Charych; Ute Hoch; John L Langowski; Steve R Lee; Murali K Addepalli; Peter B Kirk; Dawei Sheng; Xiaofeng Liu; Paul W Sims; Laurie A VanderVeen; Cherie F Ali; Thomas K Chang; Marina Konakova; Rhoneil L Pena; Rupesh S Kanhere; Yolanda M Kirksey; Chunmei Ji; Yujun Wang; Jicai Huang; Theresa D Sweeney; Seema S Kantak; Stephen K Doberstein
Journal:  Clin Cancer Res       Date:  2016-02-01       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.